Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures

Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty

(2012) Jeffrey A. Magee et al.   CANCER CELL

Further progress in HER2-directed therapy

(2012) Ian Krop et al.   LANCET ONCOLOGY

Non-Overlapping Progesterone Receptor Cistromes Contribute to Cell-Specific Transcriptional Outcomes

(2012) Christine L. Clarke et al.   PLoS One

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse

(2011) J. Chuck Harrell et al.   BREAST CANCER RESEARCH AND TREATMENT

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study

(2011) C. K. Osborne et al.   CLINICAL CANCER RESEARCH

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer

(2011) C. A. Lange et al.   ENDOCRINE-RELATED CANCER

Progress in endocrine approaches to the treatment and prevention of breast cancer

(2011) Ifeyinwa Obiorah et al.   MATURITAS

Progesterone regulation of stem and progenitor cells in normal and malignant breast

(2011) Sunshine Daddario Axlund et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

(2011) Yoko S DeRose et al.   NATURE MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers

(2011) Yao-Tseng Chen et al.   PLoS One

Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch

(2011) J. M. Haughian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers

(2010) Peter Kabos et al.   BREAST CANCER RESEARCH AND TREATMENT

Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women

(2010) Rowan T. Chlebowski et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling

(2010) C. M. Fillmore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MYC regulation of a “poor-prognosis” metastatic cancer cell state

(2010) Anita Wolfer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

(2009) Francesca De Amicis et al.   BREAST CANCER RESEARCH AND TREATMENT

Androgen Receptor Inhibits Estrogen Receptor-  Activity and Is Prognostic in Breast Cancer

(2009) A. A. Peters et al.   CANCER RESEARCH

Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature

(2009) Emmanuelle Charafe-Jauffret et al.   CANCER RESEARCH

DNA Replication Licensing and Progenitor Numbers Are Increased by Progesterone in Normal Human Breast

(2009) J. Dinny Graham et al.   ENDOCRINOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to Endocrine Therapy: Are Breast Cancer Stem Cells the Culprits?

(2009) Ciara S. O’Brien et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

(2009) Anna Bergamaschi et al.   Molecular Oncology

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

(2009) Elgene Lim et al.   NATURE MEDICINE

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

(2008) Luis O Gonzalez et al.   BMC CANCER

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance

(2008) Djuana M. E. Harvell et al.   BREAST CANCER RESEARCH AND TREATMENT

Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts

(2008) C. J. Creighton et al.   CANCER RESEARCH

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function

(2008) S. Massarweh et al.   CANCER RESEARCH

Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

(2008) Dedra H. Fagan et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts

(2008) K. B. Horwitz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA